Azvudine, a novel nucleoside as effective treatment forHIV and COVID-19 infections with potential for liver cancer.

3 weeks ago

2,842 3 minutes read

The 14th World Gastroenterology, IBD & Hepatology Conference in Holiday Inn Dubai, Al Barsha, UAE & Virtual from December 17-19, 2024.

Speaker Name: Dr. Qun Dang
Affiliation: President, Genuine Biotech
Location: China

Biography: Max received his BS from Jilin University with honors and earned a CGP Chinese national scholarship; he obtained hisPh.D. in organic chemistry from Purdue University in 1992, joined Gensia (later became Metabasis) as a medicinal chemistand worked until 2009 with his last position as director of medicinal chemistry. Max then joined Merck as a Senior Investigator in the External Basic Research department,and then from 2011 to 2013, he was Director of External Medicinal Chemistry, Asia Lead, based in Shanghai facilitating Merck-CRO operations; 2013-2016, he was a Principle Scientist in the exploratory chemistry department at the Kenilworth site. In 2016 he joined Eli Lilly as Asia Head, BD and External Innovation for diabetes and CV research and worked until March 2018 before joining Qilu Pharmaceutical as VP, Global Head of BD and External Innovation with responsibilities for all BD and external collaborations globally including in-license, out-license and setting strategies for drug discovery and external collaborations. From June 2019 to February 2021Max worked at CSPC as corporate VP, President of CSPC Shanghai Research Institute, CEO of InnovStone Therapeutics, responsible for small molecule new drug discovery efforts. In April 2021, Max joined Genuine Biotech as President and responsible for all aspects of company business including corporate strategy, R&D, financing etc. Max has extensive experiences in business development globally and more than 25-years of experiences as a manager of drug discovery programs spanning from early (Target Selection and Validation, Lead Identification) to late (Lead Optimization and candidate selection) stages; led programs that advanced multiple compounds into human clinic trials (two completed Phase 2b POC studies); experiences in therapeutic areas including diabetes, dyslipidemia, hepatitis B and C, liver cancer, liver fibrosis, anemia, viral and bacterial infections; extensive knowledge of Structure-based Drug Design, Medicinal Chemistry, Drug Delivery, Prodrugs, Liver targeting Strategies, Combinatorial, Heterocyclic and Nucleoside Chemistry; more than five years of managing drug discovery programs executed at various CROs. His research activities have led to 91 publications and 60 patents.

Global Journal of Gastroenterology & Hepatology Research [GJGHR]
Visit Speaker page: https://gastroenterology.universeconferences.com/speaker/qun-dang/

Abstract

Azvudine (FNC), first approved for HIV infections (RT inhibitor) in China, and later approved for the treatment of COVID-19 infections (RdRp inhibitor) in China and Russia. The COVID-19 pandemic has affected millions of people worldwide, therefore safe and effective oral treatments are much needed. Initially we developed FNC as an anti-HIV drug and obtainedNDA approval in 2021; since the COVID-19 outbreak FNC was discovered as a potential treatment of COVID-19 infections. Multiple clinical trials have been completed and FNC demonstrated excellent safety and efficacy profiles after oral once a day 5 mg dose, thus approved in 2022 for COVID-19 infections. Recent studies revealed that FNC has immune modulation properties and could be used in combination with PD-1 for liver cancer, producing complete CR in animal models. Herein, results for our phase 3 clinical trials and post-market real world analysis for COVID-19 infections and preclinical studies of FNC combo with PD-1 for solid tumors will be presented and discussed.